Clinical Outcomes of Pneumocystis carinii Pneumonia in Adult Liver Transplant Recipients

• Published in: Transplantation proceedings Vol. 45; no. 8; pp. 3057 - 3060
• Main Authors: Choi, Y.-I, Hwang, S, Park, G.-C, Namgoong, J.-M, Jung, D.-H, Song, G.-W, Ha, T.-Y, Moon, D.-B, Kim, K.-H, Ahn, C.-S, Lee, S.-G
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2013
• Subjects: Antibiotic Prophylaxis; Female; Humans; Liver Transplantation; Male; Middle Aged; Pneumonia, Pneumocystis - therapy; Surgery; Survival Rate
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2013.08.074

Abstract Purpose Pneumocystis carinii pneumonia (PCP) is an opportunistic infection associated with morbidity and mortality in solid-organ transplant recipients. We retrospectively assessed the characteristics and outcomes of liver transplant (OLT) recipients with PCP compared with those of patients with severe non- P carinii pneumonia (non-PCP) who required intensive care with mechanical ventilation. Methods During the 2-year period between January 2008 and December 2009, 43 adult OLT recipients had severe pneumonia requiring mechanical ventilation; of these, 8 (19%) had PCP. During this period, routine antibiotic prophylaxis was administered for the first 6 months after OLT. Results The median period from OLT to development of PCP was 9.5 months (range, 1–67); the 1-year incidence was 0.9%. The 6 and 6 to 12-month incidences of non-PCP were 4.2% and 0.3%, respectively, and those of PCP were 0.3% and 0.6%, respectively. Four of 8 patients (50%) in the PCP group had a recent history of a rejection episode. PCP was associated with a higher incidence of prior antirejection treatment. There were no significant differences between PCP and non-PCP groups in age, gender, preoperative Model for End-stage Liver Disease score, primary diagnosis, graft type, and total number of rejection episodes. Conclusions These results indicate that the risk of PCP in OLT recipients is closely related to strong immunosuppressive treatment for acute cellular rejection episodes, suggesting the importance of PCP prophylaxis in these patients. Because most patients developed PCP at around 1 year, it may be advisable to prolong routine post-OLT PCP prophylaxis for 12 months, especially among patients receiving antirejection treatment.